Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RATIONALE, DESIGN, AND ORGANIZATION OF THE METOPROLOL CR XL RANDOMIZED INTERVENTION TRIAL IN HEART-FAILURE (MERIT-HF)/
Autore:
HJALMARSON A; GOLDSTEIN S; FAGERBERG B; WEDEL H; KJEKSHUS J; WAAGSTEIN F; ELALLAF D; VITOVEC J; ALDERSHVILE J; HALINEN M; DIETZ R; NEUHAUS KL; JANOSI A; THORGEIRSSON G; DUNSELMAN PHJM; GULLESTAD L; KUCH J; HERLITZ J; RICKENBACHER P; BALL SG; GOTTLIEB S; DEEDWANIA P; CHATTERJEE K; DEMETS D; JULIAN D; LEHTO S; MOTZ W; SAMUELSSON O; ANDERSSON B;
Indirizzi:
SAHLGRENS UNIV HOSP,WALLENBERG LAB CARDIOVASC RES S-41345 GOTHENBURG SWEDEN SAHLGRENS UNIV HOSP,WALLENBERG LAB CARDIOVASC RES S-41345 GOTHENBURG SWEDEN
Titolo Testata:
The American journal of cardiology
fascicolo: 9B, volume: 80, anno: 1997,
pagine: 54 - 58
SICI:
0002-9149(1997)80:9B<54:RDAOOT>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
DILATED CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; MORTALITY; BLOCKERS; SURVIVAL; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
A. Hjalmarson et al., "RATIONALE, DESIGN, AND ORGANIZATION OF THE METOPROLOL CR XL RANDOMIZED INTERVENTION TRIAL IN HEART-FAILURE (MERIT-HF)/", The American journal of cardiology, 80(9B), 1997, pp. 54-58

Abstract

Metoprolol is a cardioselective beta blocker that has been shown to improve left ventricular function and symptoms of congestive heart failure (CHF) and also to decrease the number of hospitalizations due to CHF. However, the effects of metoprolol on mortality in patients with CHF have yet to be determined, Accordingly, the Metoprolol CR/XL Randomized intervention Trial in Heart Failure (MERIT-HF) has been designed to investigate the effect of once-daily dosing of metoprolol succinatecontrolled release/extended release (CR/XL) when added to standard therapy in patients with CHF. A total of 3,200 patients will be recruited for this international, double-blind, randomized, placebo-controlledsurvival study. The 2 primary objectives of MERIT-HF are to determinethe effect of metoprolol CR/XL on (1) total mortality and (2) the combined endpoint of all-cause mortality and all-cause hospitalizations (time to first event). Eligible patients are 40-80 years old, with a reduced left ventricular ejection fraction (less than or equal to 0.40) and symptoms of CHF (New York Heart Association functional classes II-IV). After a 2-week placebo run-in period, an optimal allocation procedure will be used to randomize patients in a 1:1 ratio to metoprolol CR/XL or matching placebo, After an initial titration phase starting with 12.5 mg or 25 mg once daily (depending on functional class), the target dose will be 200 mg in all patients who tolerate this dose. The mean follow-up is estimated to be 2.4 years, The study data will be analyzed on an intention-to-treat basis. An Independent Safety Committee will monitor the safety aspects of the trial, and an Independent Endpoint Committee will classify all endpoints. (C) 1997 by Excerpta Medica, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 20:12:55